NCT01867645 - The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2011

Conditions

Polyneuropathies

Interventions

DRUG

IgM-enriched Intravenous Immunoglobulins

IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.

DRUG

Human Albumin

Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days

Trial Locations (1)

1090

Medical University of Vienna, Vienna